Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm
Open Access
- 1 January 2021
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (1), 120-121
- https://doi.org/10.1002/jmv.26209
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJama-Journal Of The American Medical Association, 2020
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)Microorganisms, 2020
- Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patientsMedecine Et Maladies Infectieuses, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020
- Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-192020
- Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 InfectionCell, 2020
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionLancet, 2020
- Sample size estimation in clinical trial.2010